BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Navlimetostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Navlimetostat\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07777133-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT07777133)
DESCRIPTION:Navlimetostat\, phase 1.\nStudy: A Study to Evaluate the Metabo
 lism\, the Routes and Extent of Elimination\, and Drug Levels of [14C]Navl
 imetostat (BMS-986504) in Healthy Female Participants\nEstimated primary c
 ompletion: 5 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/navlimetostat#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07777133
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07077434-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT07077434)
DESCRIPTION:Navlimetostat\, phase 1.\nStudy: A Study to Assess Safety\, Tol
 erability and Drug Levels of Navlimetostat (BMS-986504) in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: 19 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07077434
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07800897-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT07800897)
DESCRIPTION:Navlimetostat\, phase 1.\nStudy: A Study of Navlimetostat (BMS-
 986504) Drug Interactions and Food Effect in Healthy Participants\nEstimat
 ed primary completion: 25 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/navlimetostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07800897
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602946-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Navlimetostat: Phase 2 readout est. (NCT07602946)
DESCRIPTION:Navlimetostat\, phase 2.\nStudy: SELECTmeso A Trial for Patient
 s With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 i
 n Patients With MTAP-deficient Relapsed Mesothelioma\nEstimated primary co
 mpletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 navlimetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07602946
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672523-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT06672523)
DESCRIPTION:Navlimetostat\, phase 1.\nStudy: A Study to Evaluate the Mass B
 alance\, Metabolism\, Elimination\, and Drug Levels of [14C]-BMS-986504 (M
 RTX1719) in Participants With Advanced Solid Tumors With Homozygous Methyl
 thioadenosine Phosphorylase Deletion\nEstimated primary completion: 25 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/navlimetos
 tat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06672523
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05245500-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT05245500)
DESCRIPTION:Navlimetostat\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion\nEstimated pri
 mary completion: 10 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/navlimetostat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05245500
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549022-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Navlimetostat: Phase 1/2 readout est. (NCT07549022)
DESCRIPTION:Navlimetostat\, phase 1/2.\nStudy: Safety and Efficacy of BMS-9
 86504 in Unresectable Malignant Peripheral Nerve Sheath Tumor\nEstimated p
 rimary completion: April 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/navlimetostat#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07549022
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Navlimetostat: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Navlimetostat\, phase 2.\nStudy: A Study of Navlimetostat (BMS-
 986504) Monotherapy and in Combination With Other Agents in Participants W
 ith Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion 
 (MountainTAP-5)\nEstimated primary completion: 15 August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855771-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Navlimetostat: Phase 2 readout est. (NCT06855771)
DESCRIPTION:Navlimetostat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalonta
 mab Brengitecan in Participants With Pre-treated Advanced or Metastatic No
 n-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Los
 s (MountainTAP-9)\nEstimated primary completion: 29 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06855771
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532902-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT07532902)
DESCRIPTION:Navlimetostat\, phase 1.\nStudy: A Study of BMS-986504 With Sta
 ndard-of-Care Therapy for People With Solid Tumor Cancer\nEstimated primar
 y completion: April 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/navlimetostat#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07532902
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076121-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Navlimetostat: Phase 2/3 readout est. (NCT07076121)
DESCRIPTION:Navlimetostat\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\n
 Study: A Study Comparing Navlimetostat (BMS-986504) in Combination With Na
 b-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclit
 axel and Gemcitabine in Participants With Untreated Metastatic Pancreatic 
 Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)\nEsti
 mated primary completion: 3 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/navlimetostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07076121
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905131-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Navlimetostat: Phase 1/2 readout est. (NCT07905131)
DESCRIPTION:Navlimetostat\, phase 1/2\, Pancreatic Ductal Adenocarcinoma.\n
 Study: A Study of Perioperative Navlimetostat Combined With Modified FOLFI
 RINOX in Patients With MTAP-Deleted Pancreatic Cancer\nEstimated primary c
 ompletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/navlimetostat#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07905131
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579221-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Navlimetostat: Phase 1/2 readout est. (NCT07579221)
DESCRIPTION:Navlimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced No
 n-Small Cell Lung Cancer\nEstimated primary completion: 1 August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07579221
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283705-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Navlimetostat: Phase 2 readout est. (NCT07283705)
DESCRIPTION:Navlimetostat\, phase 2.\nStudy: A Phase II Study Evaluating BM
 S-986504 in MTAP-deleted Pancreatic Cancer\nEstimated primary completion: 
 1 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/navli
 metostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07283705
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382544-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Navlimetostat: Phase 1 readout est. (NCT07382544)
DESCRIPTION:Navlimetostat\, phase 1.\nStudy: Phase 1b Trial of BMS-986504 i
 n Combination With Olaparib in Patients With MTAP Loss\nEstimated primary 
 completion: 31 January 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/navlimetostat#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07382544
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594626-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20301209
DTEND;VALUE=DATE:20301210
SUMMARY:Navlimetostat: Phase 1/2 readout est. (NCT07594626)
DESCRIPTION:Navlimetostat\, phase 1/2.\nStudy: BMS-986504 in Combination Wi
 th Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Delet
 ion\nEstimated primary completion: 9 December 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/navlimetostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07594626
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-2283@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Navlimetostat: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Navlimetostat\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pem
 brolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemothe
 rapy in First-line Metastatic Non-small Cell Lung Cancer Participants With
  Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
